PBM FAIR Act
Summary
The PBM FAIR Act (S3549) imposes ERISA fiduciary duty on UNH's Optum Rx, CVS's Caremark, and CI's Express Scripts, eliminating undisclosed rebates and spread pricing. Despite a 30-day rally of +36.2% in UNH, +16.35% in CVS, and +9.1% in CI, this early-stage bill creates a multi-year overhang that would reverse those gains upon legislative progress. Current pricing embeds zero probability of passage — real data shows UNH at $368.56, CVS at $83.56, CI at $291.02.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.PBM FAIR Act forces fiduciary duty on Big 3 PBMs, eliminating ~$7-11B in annual profits from undisclosed rebates and spread pricing.
- 2.Current stock prices (UNH $368.56, CVS $83.56, CI $291.02) reflect zero legislative risk despite 30-day rallies of 9-36%.
- 3.Bipartisan sponsors in both chambers (S3549 and HR6837) give this bill multi-year staying power regardless of 2026 election outcomes.
- 4.Even early-stage progress (hearings, CBO score) would trigger downside repricing in UNH, CVS, and CI.
Market Implications
The PBM FAIR Act creates a multi-year regulatory overhang on the Big 3 PBM stocks. Current market pricing — UNH at $368.56 (up 36.2% in 30 days), CVS at $83.56 (up 16.35%), CI at $291.02 (up 9.1%) — has entirely ignored this risk. A conservative estimate suggests 15-25% downside for these three stocks upon any credible legislative movement (committee markup or CBO score). The asymmetry favors shorts or puts: the bill progressing is not priced in, while the bill dying is already the base case. Investors should monitor Schedule C of the Senate HELP Committee and any CRS reports for early signals of movement.
Full Analysis
-
What happened: Senator Marshall (R-KS) introduced S3549 on December 17, 2025, along with cosponsors Kaine (D-VA), Grassley (R-IA), and Hassan (D-NH). The bill was read twice and referred to the Committee on Health, Education, Labor, and Pensions. Companion bill HR6837 was introduced in the House. The bill is early-stage — no hearings, no markup, no CBO score. The 119th Congress session runs through January 2027, giving this bill a full calendar year to advance.
-
Money trail: This bill authorizes $0 in new spending. Its mechanism is regulatory — it redesignates PBMs as ERISA fiduciaries, creating legal obligations and liability. The financial impact is on PBM profit margins, not government appropriations. The bill forces PBMs to disclose and pass through all manufacturer rebates, fees, and price concessions to plan sponsors (employers, unions, insurers). Spread pricing — where PBMs charge plans more than they reimburse pharmacies — is effectively banned because the PBM must report all compensation earned.
-
Structural winners and losers: The Big 3 PBMs — Optum Rx (UNH), Caremark (CVS), and Express Scripts (CI) — are the direct losers. They would lose an estimated $7-11B in combined annual profit from rebate retention and spread pricing. Smaller, transparent PBMs like Evernorth's competition (e.g., Navitus, SmithRx, Capital Rx — all private) would benefit as plan sponsors shift to fiduciaries. Health insurers with in-house PBMs (UNH, CI) face double impact: reduced PBM profit and potential insurance premium adjustments as rebate pass-throughs lower drug costs for plans. Pharmacy chains (Walgreens/WBA, Rite Aid/RADCQ) may benefit marginally as spread elimination increases pharmacy reimbursement rates.
-
Real market data analysis: UNH has rallied 36.2% in 30 days to $368.56, but remains below its 52-week high of $411.99. CVS is up 16.35% in 30 days to $83.56, approaching its 52-week high of $85.15. CI is up 9.1% in 30 days to $291.02, well below its 52-week high of $350. The rally appears driven by Q1 2026 earnings beats and broader market rotation into value/healthcare, not by legislative risk reassessment. The 7-day changes (UNH +3.84%, CVS +7.21%, CI +5.58%) show accelerating momentum, suggesting the market is pricing in continued operational strength, not the PBM FAIR Act Overhang. This creates downside risk: any meaningful legislative progress (committee markup, CBO score, floor vote) would trigger a repricing.
-
Timeline: Early-stage bill with 4 sponsors (2 Republicans, 2 Democrats) — bipartisan but not committee leadership. Grassley (ranking member of Senate Finance) adds weight. A companion bill in the House (HR6837) increases passage probability long-term. Next milestones: committee hearings (6-12 months for a non-priority bill), markup, potential floor vote. Realistically, this bill has a 20-30% chance of passage this Congress, but even hearings would create headline risk for PBM stocks.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
Multiple independent sources confirm this signal’s market thesis
What the bill does
Fiduciary duty mandate — PBMs deemed ERISA fiduciaries, requiring full disclosure of all indirect compensation (rebates, fees, price concessions) and prohibiting undisclosed spread pricing.
Who must act
Optum Rx (UnitedHealth Group subsidiary), as one of the Big 3 PBMs managing prescription drug networks, formularies, claims processing, and rebate aggregation for group health plans.
What happens
Optum Rx must report and pass through all manufacturer rebates and fees to plan sponsors; spread pricing between pharmacy reimbursement and plan charges is eliminated; estimated 15-25% reduction in PBM segment profit margin.
Stock impact
UNH's Optum segment generated ~$60B in PBM-related revenue in FY2025; the bill would eliminate undisclosed spread (~10-12% of PBM revenue) and forced rebate pass-through reduces float income. Combined impact could reduce UNH's total earnings by $3-5B annually, representing 8-12% of UNH's operating income.
What the bill does
Fiduciary duty mandate — Caremark (CVS Health subsidiary) deemed ERISA fiduciary, requiring full pass-through of rebates and fees, elimination of spread pricing on pharmacy claims.
Who must act
CVS Caremark, one of the Big 3 PBMs, managing drug formularies, negotiating manufacturer rebates, and processing pharmacy claims for approximately 65 million plan members.
What happens
Caremark loses ability to retain manufacturer rebates as profit; spread pricing on generic drugs (where Caremark pays pharmacy $A and charges plan $B, pocketing the difference) is eliminated; estimated 20-30% reduction in PBM operating profit.
Stock impact
CVS Health's PBM segment (Caremark) contributes ~40% of company operating income (~$7B annually). Elimination of spread pricing and forced rebate pass-through would reduce PBM profit by $1.4-2.1B. CVS also faces pharmacy reimbursement compression as retail margins are squeezed by transparency.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Association Health Plans Act
TRIWEST HEALTHCARE ALLIANCE CORP: $820M Department of Veterans Affairs Contract
Living Donor Protection Act of 2025
Veterans’ ACCESS Act of 2025
Protecting Health Care and Lowering Costs Act of 2025
Consolidated Appropriations Act, 2026
Veteran Caregiver Reeducation, Reemployment, and Retirement Act
Medicare for All Act
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Implementing Schedule Policy/Career in the Excepted Service
This executive order expands the Schedule Policy/Career excepted service category, transferring certain federal positions from competitive service to at-will employment to facilitate removal for poor performance or misconduct. It directs agency heads to petition for reclassification of policy-influencing roles, mandates performance bonus pools for these employees, and amends civil service rules to exempt them from standard adverse action procedures.
Realigning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries
This executive order directs the CDC and ACIP to review and potentially update the U.S. childhood vaccine schedule to align with recommendations from peer developed countries, which recommend fewer vaccines. It maintains insurance coverage for all currently available vaccines without cost sharing and emphasizes protecting religious liberty and parental authority.
Promoting Efficiency, Accountability, and Performance in Federal Contracting
This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.